Von E confirmation reheats
This article was originally published in The Tan Sheet
Senate Finance chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach's nomination for FDA Commissioner Nov. 17. Grassley objects to the acting commissioner's failure to comply with subpoenas the committee issued in May for FDA documents related to Sanofi-Aventis' antibiotic Ketek. "The authority and integrity of Senate and Committee processes are being challenged," says Grassley. A day earlier, during a hearing on drug safety, Senate Health Committee Chairman Michael Enzi (R-Wyo.) urged colleagues to take up a vote on the nominee. "Give Dr. von Eschenbach the chance to effectively run the FDA with full statutory authority," Enzi said. Holds from Sen. David Vitter (R-La.) and Sen. Jim DeMint (R-S.C.) also remain in place. After the hearing, Enzi told reporters he continues working to lift those holds. If action is not taken during the lame duck session, incoming chair Edward Kennedy (D-Mass.), who supports the nomination, appears likely to continue to press for confirmation...
You may also be interested in...
Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.